Back to Results
First PageMeta Content
Pharmacology / Biology / Hepatology / Hepatitis / Pyrazines / Telaprevir / Boceprevir / Peginterferon alfa-2a / Hepatitis C / Medicine / Antivirals / Protease inhibitors


Interim Clinical Commissioning Policy Statement: Simeprevir for treating Genotype 1 Chronic Hepatitis C Reference: NHS England A02/PS/c
Add to Reading List

Document Date: 2015-01-14 05:24:48


Open Document

File Size: 149,54 KB

Share Result on Facebook

City

Orlando / Amsterdam / Washington DC / Brisbane / London / Brussels / /

Company

BOC / the AEs / /

Country

Pakistan / United Kingdom / /

Currency

GBP / /

Event

Product Issues / /

IndustryTerm

NICE technology appraisals / HCV therapy / technology appraisals / HCV treatment / NICE technology appraisal / /

MedicalCondition

Q80K negative hepatitis C / HIV / disease / liver failure / hepatocellular carcinoma / chronic HCV / nausea / cirrhosis / hepatitis C / England A02/PS/c The hepatitis C / HCV / itching / pain / HCV infection / fatigue / encephalopathy / liver cancer / chronic hepatitis C. The / hypersensitivity / infection / chronic hepatitis / advanced liver disease / inflammation / liver disease / depression / pruritus / infections / chronic hepatitis C A02 / rash / chronic hepatitis C / fibrosis / HCV genotype / HCV RNA / /

MedicalTreatment

drug therapy / /

Organization

To commission / NHS / /

Position

A02/PS/C Author / /

Product

ribavirin / peginterferon / blood / /

ProvinceOrState

Hawaii / /

Technology

transplantation / Genotype / /

URL

www.england.nhs.uk/commissioning / /

SocialTag